BIOTOSCANA INVESTMENTS S.A.
Corporate Taxpayer’s ID (CNPJ/MF): 19.688.956./0001-56
24, Rue Beck, L 1222, Luxembourg
Legal representative in Brazil: Av. dos Imarês, 401, São Paulo, SP

NOTICE TO THE MARKET

Grupo Biotoscana announces extension of agreement with Biocad to include exclusive license for Infliximab in Colombia

BIOTOSCANA INVESTMENTS S.A. ("Company" or "GBT") (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that it has made an amendment to the agreement with JSC Biocad, a Russian innovative biotechnology company, to exclusively register, market and commercialize Infliximab in Colombia.

Under the existing agreement, GBT is responsible for the marketing authorizations, market access, commercialization and distribution of Rituximab, Bevacizumab, Trastuzumab and Adalimumab in four countries and now for Infliximab in Colombia.

Montevideo, March 2, 2018

BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal Representative in Brazil

About GBT-Grupo Biotoscana
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more, please visit www.grupobiotoscana.com.
About INFLIXIMAB
INFLIXIMAB is a monoclonal antibody that works to enhance and improve the immune system indicated to be used in adults to treat Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. It is also used in children to treat Crohn disease and ulcerative colitis. INFLIXIMAB reported in 2016 an annual sales close to USD 7B worldwide.

About RITUXIMAB
RITUXIMAB is a monoclonal antibody used alone or with other medicines to treat a type of cancer called non-Hodgkin’s lymphoma (NHL). It helps the immune system destroy cancer cells. RITUXIMAB is used together with fludarabine and cyclophosphamide to treat a type of cancer called chronic lymphocytic leukemia (CLL) and it is also used together with methotrexate to treat the symptoms of rheumatoid arthritis. It helps to keep joint damage from getting worse after at least one other medicine has been used and did not work well. RITUXIMAB is used together with steroids to treat granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) and microscopic polyangiitis (MPA). These are immune disorders that cause blood vessels to be inflamed. RITUXIMAB reported annual worldwide sales of CHF 7.3B in 2016.

About BEVACIZUMAB
BEVACIZUMAB is a monoclonal antibody that helps the body to fight cancer. BEVACIZUMAB is given with other medicines to treat patients with metastatic (a cancer that has spread) carcinoma of the colon or rectum. This medicine is also used to treat a certain type of metastatic lung cancer called nonsquamous, non-small cell lung cancer, and a certain type of brain tumor called glioblastoma. BEVACIZUMAB is also used in combination with other medicines to treat patients with cancer of the kidney and cancer of the cervix that has spread to other areas of the body. This medicine is also used in combination with other medicines to treat patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. BEVACIZUMAB reported annual sales of CHF 6.7B worldwide in 2016.

About TRASTUZUMAB
TRASTUZUMAB is a monoclonal antibody used to treat new cases of breast cancer or disease that has spread to other parts of the body. It may prevent the growth of some breast tumors that produce extra amounts of a certain substance known as the HER2 protein. TRASTUZUMAB is also used in combination to treat malignant tumor of the stomach and esophagogastric (esophagus and stomach) cancer, metastatic, HER2 overexpression. TRASTUZUMAB reported annual sales of CHF 6.7B worldwide in 2016.

About ADALIMUMAB
ADALIMUMAB is a monoclonal antibody used to treat the symptoms and prevent the progression of active rheumatoid arthritis and ankylosing spondylitis. It is used in children 2 years of age and older for juvenile idiopathic arthritis. This medicine is also used to treat psoriatic arthritis, which is a type of arthritis that causes pain and swelling in the joints along with patches of scaly skin on some areas of the body. ADALIMUMAB injection is also used to treat the symptoms of active Crohn's disease in patients who have not been helped by other medicines. It is also used to treat moderate to severe to severe ulcerative colitis in patients who have been treated with other medicines that did not work well.
ADALIMUMAB may also be used to treat chronic plaque psoriasis, which is a skin disease with red patches and white scales that don’t go away. It is also used to treat moderate to severe hidradenitis suppurativa, a chronic skin disease that has small, painful lumps under the skin. This medicine is also used to treat non-infectious intermediate, posterior and panuveitis in adults. ADALIMUMAB reported annual sales of USD 16B worldwide in 2016.

Forward-Looking Statements (GBT)
This release includes forward-looking statements concerning a transaction between GBT-Grupo Biotoscana and Biocad, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.